Clinical trials: Rectal Cancer, Radiotherapy
Prostate Carcinoma, Rectum Carcinoma
Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation
Bone marrow is one of the organs at risk of complications during irradiation due to its radiosensitivity. Hematopoietic toxicity remains one of the main toxicities during irradiation of pelvic lymph node areas, especially when…
- Conditions
- Prostate Carcinoma, Rectum Carcinoma, Anal Canal Carcinoma, Endometrium Carcinoma
- Trial name
- MIFADORESOL (NCT04626466)
- Testing
- Biological investigations
- Where
- 3 sites in France
- Volunteers
- 100 people
- Sponsor
- Institut de cancérologie Strasbourg Europe
Uterine Cervical Neoplasms, Endometrial Neoplasms
[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
[F-18] Fluorothymidine PET imaging will be used to create a radiation therapy treatment plan to avoid active bone marrow in the pelvis. This will be done to evaluate if sparing bone marrow will help maintain blood counts.
- Conditions
- Uterine Cervical Neoplasms, Endometrial Neoplasms, Anus Neoplasms, Rectal Neoplasms
- Trial name
- NCT01717391
- Testing
- fluorothymidine F 18
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- John M. Buatti
Prostate Cancer
Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients With Prostate Cancer
This phase II trial studies the effect of rectal spacer hydrogel before radiation therapy in reducing radiation dose to the rectum in patients with prostate cancer.
- Trial name
- NCT05224869
- Testing
- Medical Device Usage and Evaluation, CT simulation, Stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Colorectal Cancer
CITRuS Stage 1; Feasibility
Bowel cancer is the third most common cancer occurring in the UK. Treatment usually involves surgery, often with chemotherapy or radiotherapy.
- Trial name
- CITRuS1 (NCT04697394)
- Where
- United Kingdom
- Volunteers
- 380 people
- Sponsor
- Royal Surrey County Hospital NHS Foundation Trust
Rectal Neoplasm Malignant
Metabolomics to Predict Treatment Response and Toxicities in Rectal Cancer
Background: Colorectal cancer is the leading cause of cancer-related deaths in Taiwan, with rectal cancer accounting for approximately 27% of all cases.
- Trial name
- NCT06831669
- Testing
- Collecting biospecimens
- Where
- Taiwan
- Volunteers
- 250 people
- Sponsor
- Chang Gung Memorial Hospital
Anal Cancer
Functional Outcomes Following Anal Cancer Treatment
Anal cancer is treated with chemoradiotherapy- combined chemotherapy and radiotherapy. This is very successful (75% long term survival). During the course of the radiotherapy, other organs in the pelvis may be damaged.
- Trial name
- FOFACT (NCT01853059)
- Where
- 2 sites in United Kingdom
- Volunteers
- 176 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Rectal Cancer
Short-Course Radiotherapy Followed by Immunotherapy Combined With Chemotherapy for Microsatellite Stable Locally Advanced Rectal Cancer: A Prospective, Randomized, Controlled Phase II Clinical Trial
Microsatellite stable (MSS) locally advanced rectal cancer (LARC) remains a major therapeutic challenge despite advances in multimodal treatment.
- Trial name
- NCT07594925
- Testing
- Sintilimab, Chemotherapy Drugs, radiotherapy
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Colorectal Cancer, Metastases
Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer
This study tries to evaluate the role of chemoradiation with capecitabine and bevacizumab in oligometastatic patients neither being progressive nor resectable after chemotherapy.
- Trial name
- OLGA (NCT01759238)
- Testing
- Capecitabine, Bevacizumab, Radiotherapy
- Where
- Germany
- Volunteers
- 1 people
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Colorectal Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00268333
- Testing
- fluorouracil, leucovorin calcium, oxaliplatin
- Where
- 9 sites in France
- Volunteers
- 39 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer
Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer
This randomized phase II trial evaluates the efficacy of long-course chemoradiotherapy (50Gy/25Fx + capecitabine) versus short-course radiotherapy (25Gy/5Fx) combined with CAPOX（Capecitabine and Oxaliplatin）, PD-1 inhibitor…
- Trial name
- NCT07154316
- Testing
- LCRT, SCRT, CAPOX
- Where
- 5 sites in China
- Volunteers
- 138 people
- Sponsor
- Fudan University
Rectal Cancer, Locally Advanced
Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer
A Single-arm phase II trial evaluating induction chemotherapy with FOLFIRINOXm followed by short course radiotherapy (RT) in locally advanced rectal carcinoma
- Trial name
- NCT05868317
- Testing
- Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan), Radiotherapy
- Where
- Tunisia
- Volunteers
- 70 people
- Sponsor
- Salah Azaïz Cancer Institute
Rectum Adenocarcinoma
Fibroblast Before and After Neoadjuvant Chemo-radiotherapy in Patient With Locally Advanced Rectal Adenocarcinoma
Single center interventional study to explore activity of fibroblasts in the tumor and away in the healthy rectal tissue.
- Trial name
- FibroRect (NCT02849158)
- Testing
- Biopsy
- Where
- 3 sites in France
- Volunteers
- 14 people
- Sponsor
- Institut Curie
Rectal Cancer
Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy, HLX07and Serplulimab in LARC
The study is a multicenter, open-label, phase II clinical study, and the purpose of the study is to explore the complete response rate (CR, Defined as pathological complete response (pCR) + Clinical complete response (cCR)) of…
- Trial name
- NCT06542588
- Testing
- HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)
- Where
- 3 sites in China
- Volunteers
- 29 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Rectal Neoplasms
Predictive Factors of Disease-free Survival After Complete Pathological Response to Neoadjuvant Radiotherapy in Rectal Adenocarcinoma
Many data suggest that patients with low rectal adenocarcinoma who achieved ypT0N0 status have improved survival and disease-free survival (DFS) compared to all other stages however only few data are available regarding the…
- Trial name
- NCT03601689
- Testing
- rectal resection
- Where
- 8 sites in Algeria, Morocco
- Volunteers
- 84 people
- Sponsor
- Moroccan Society of Surgery
Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7
Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
This phase I trial studies the side effects and best dose of ropidoxuridine in treating patients with gastrointestinal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment…
- Conditions
- Advanced Bile Duct Carcinoma, Stage II Esophageal Cancer AJCC v7, Stage II Pancreatic Cancer AJCC v6 and v7, Stage IIA Esophageal Cancer AJCC v7
- Trial name
- NCT02381561
- Testing
- Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Neoplasm
Intraoperative Radiotherapy for Rectal Cancer Using the Photon Radiosurgery System
The investigators would like to test the safety and efficacy of intraoperative radiotherapy (IORT) in rectal cancer using the Photon Radiosurgery System (PRS).
- Trial name
- NCT00910494
- Testing
- Photon Radiosurgery System IORT
- Where
- United Kingdom
- Volunteers
- 9 people
- Sponsor
- University of Dundee
Rectal Cancer
Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer
This is phase 2 trial of neoadjuvant therapy and short-course radiotherapy in resectable rectal cancer.
- Trial name
- NCT04643366
- Testing
- Chemotherapy, Radiation Therapy
- Where
- 4 sites in United States
- Volunteers
- 64 people
- Sponsor
- Virginia Commonwealth University
Rectal Cancer
Preoperative Hyperfractionated Radiotherapy or Radiochemotherapy in Locally Advanced Rectal Cancer.
Clinical objective of the study is to compare the rates of pathologic response, acute toxicity and sphincter preservation with two schedules of preoperative regiment in patients with locally advanced rectal cancer.
- Trial name
- NCT01814969
- Testing
- Hyperfractionated Radiochemotherapy, Hyperfractionated Radiotherapy
- Where
- Poland
- Volunteers
- 260 people
- Sponsor
- Maria Sklodowska-Curie National Research Institute of Oncology
Colorectal Cancer
Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy
For locally advanced rectal cancer, the initial goal of neoadjuvant chemoradiotherapy is to reduce local recurrence, but the pathologic complete response (PCR) rate is low, and distant metastasis becomes the main treatment…
- Trial name
- NCT06099951
- Testing
- Serplulimab + FOLFOXIRI, Radiation therapy
- Volunteers
- 53 people
- Sponsor
- Sun Yat-sen University
Recurrent Rectal Cancer
Preoperative Chemoradiotherapy and Toripalimab in Locally Recurrent Rectal Cancer
The study is a prospective, single-center, single-arm, phase II clinical trial. Patients with pelvic recurrent rectal cancer aged from 18 to 75 years, Eastern Cooperative Oncology Group performance status of 0-1, will receive…
- Trial name
- TRACER (NCT06751394)
- Testing
- PD-1 antibody (Toripalimab), Capecitabine, Oxaliplatin
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University